Control of Peritoneal Dissemination with Sequential Methotrexate and 5-Fluorouracil

  • Toshiro Konishi
  • Tamaki Noie
  • Kenichi Mafune
  • Masatoshi Makuuchi
  • Junji Yoshida


Methotrexate (MTX), a folic acid antagonist, inhibits dihydrofolate reductase (DHFR), suppressing the reduction of folates (FH2) and causing a decrease in folates of reduced form (FH4) [1]. Through this mechanism, MTX is able to exert an antitumor effect by inhibiting DNA synthesis. Monotherapy with MTX for gastric cancer is not sufficiently effective, however, and reports of its use alone in gastric cancer patients have been rare [2]. Currently, the mainstream chemotherapy for gastric cancer employs a combination of agents, and MTX is usually used in combination with other drugs, such as 5-fluorouracil (5-FU). Pretreatment with MTX followed by 5-FU (sequential MTX and 5-FU), as proposed by Bertino et al. in 1977 [3], exerts a type of biochemical modulation in which the antitumor effect of 5-FU is enhanced by the preceding MTX.


Gastric Cancer Gastric Cancer Patient Advanced Gastric Cancer Ascitic Fluid Peritoneal Dissemination 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Chabner BA (1982) Methotrexate. In: Pharmacologic principles of cancer treatment. Saunders, Philadelphia p 229Google Scholar
  2. 2.
    Bruckner HW, Lokich JJ, Stablein DM (1982) Studies of Baker’s antifol, methotrexate, and razoxane in advanced gastric cancer: a gastrointestinal tumor study group report. Cancer Treat Rep 66:1713–1717PubMedGoogle Scholar
  3. 3.
    Bertino JR, Sawicki W, Lindquist CA, et al (1977) Schedule-dependent antitumor effects of methotrexate and 5-fluorouracil. Cancer Res 37:327–328PubMedGoogle Scholar
  4. 4.
    Konishi T, Hiraishi M, Mafune K, et al (1994) Therapeutic efficacy and toxicity of sequential methotrexate and 5-fluorouracil in gastric cancer. Anticancer Res 14:1277–1280PubMedGoogle Scholar
  5. 5.
    Sowa M, Kato Y, Nishimura M, et al (1989) Clinicohisto-chemical studies on type 4 carcinoma of the stomach with special reference to mucopolysaccharides and sialic acid in tumor tissue. Jpn J Surg 19:153–162PubMedCrossRefGoogle Scholar
  6. 6.
    Murakami M, Miyazaki T, Niitsu Y, et al (1987) Sequential methotrexate-5-fluorouracil (MTX-5-FU) treatment for patients with advanced gastric and colorectal cancer, (in Japanese with English abstract). Jpn J Cancer Chemother 14:2482–2490Google Scholar
  7. 7.
    Sasaki T, Ota K, Ibayashi J, et al (1989) Randomized multicenter trial of sequential methotrexate and 5-fluorouracil versus 5-fluorouracil alone in advanced gastric cancer, (in Japanese with English abstract). Jpn J Cancer Chemother 16:2545–2555Google Scholar
  8. 8.
    Cadman E, Heimer R, Devis L (1979) Enhanced 5-fluorouracil nucleotide formation after methotrexate administration; explanation for drug synergism. Science 205:1135–1137PubMedCrossRefGoogle Scholar
  9. 9.
    Fernandes D, Bertino JR (1980) 5-Fluorouracil methotrexate synergy: enhancement of 5-fluorodeoxyuridylate binding to thymidylate synthase by dihydropteroylpolyglutamates. Proc Natl Acad Sci USA 77:5663–5667PubMedCrossRefGoogle Scholar
  10. 10.
    Konishi T, Miyama T, Sakamoto S, et al (1992) Activities of thymidylate synthetase and thymidine kinase in gastric cancer. Surg Oncol 1:215–221PubMedCrossRefGoogle Scholar
  11. 11.
    Mizumoto K, Sawada T, Furamoto T, et al (1995) A case report: postoperative recurrence of peritoneal dissemination of gastric cancer responding to sequential methotrexate and 5-FU (5-fluorouracil) (in Japanese with English abstract). Jpn J Cancer Chemother 22:281–284Google Scholar
  12. 12.
    Kosaka T, Tsuchiya K, Sugaya J, et al (1996) A study of arterial infusion chemotherapy for gastric cancer patients with peritoneal metastasis (in Japanese with English abstract). Jpn J Cancer Chemother 23:1467–1471Google Scholar
  13. 13.
    Kitamura M, Arai K, Iwasaki Y (1996) Arterial infusion chemotherapy for advanced gastric cancer by sequential MTX/5-FU (in Japanese with English abstract). Jpn J Cancer Chemother 23:1464–1466Google Scholar
  14. 14.
    Takamatsu S, Maruyama M, Sugano N, et al (1995) Intraperitoneal infusion therapy of MTX and 5-FU for advanced gastric cancer and its peritoneal metastasis (in Japanese with English abstract). Jpn J Cancer Chemother 22:1619–1621Google Scholar
  15. 15.
    Thyss A, Milano G, Kubar J, et al (1986) Clinical and pharmacokinetic evidence of a life-threatening interaction between methotrexate and ketoprofen. Lancet Feb.1: 256–258Google Scholar
  16. 16.
    Stoller RG, Hande KR, Jacob SA, et al (1977) Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity. N Engl J Med 297:630–634PubMedCrossRefGoogle Scholar
  17. 17.
    Konishi T (1996) Treatment of scirrhous carcinoma of the stomach. Asian Med J 39:291–299Google Scholar
  18. 18.
    Konishi T, Hiraishi M, Kajiura N, et al (1995) Postoperative low-dose sequential methotrexate and 5-fluorouracil in palliative resected Borrmann type 4 gastric cancer. Proc Am Soc Clin Oncol 14:218Google Scholar
  19. 19.
    Miyashita K, Kitamura M, Arai K (1992) Effective treatment for liver metastasis and peritoneal dissemination of gastric cancer using intra-arterial therapy: a case report (in Japanese with English abstract). Jpn J Cancer Chemother 19:1749–1752Google Scholar
  20. 20.
    Shibata N, Tamai M, Ikeda K (1995) Case report of long-term survivor of advanced gastric cancer associated with peritoneal seeding successfully treated with cancer chemotherapy (in Japanese with English abstract). Jpn J Cancer Chemother 22:119–122Google Scholar

Copyright information

© Springer Japan 1999

Authors and Affiliations

  • Toshiro Konishi
    • 1
  • Tamaki Noie
    • 1
  • Kenichi Mafune
    • 2
  • Masatoshi Makuuchi
    • 2
  • Junji Yoshida
    • 3
  1. 1.Department of SurgeryKanto Teishin HospitalTokyoJapan
  2. 2.Second Department of Surgery, Faculty of MedicineUniversity of TokyoTokyoJapan
  3. 3.Department of Thoracic OncologyNational Cancer Center Hospital EastChibaJapan

Personalised recommendations